Medicis Undeterred By Inamed’s Breast Implant Panel Woes
This article was originally published in The Gray Sheet
Executive SummaryMedicis has no immediate plans to revisit the financial details of its pending acquisition of Inamed, despite last week's negative FDA panel decision on the latter company's silicone breast implants
You may also be interested in...
The FDA’s OPQ touts approval of sixth and seventh continuously manufactured drugs and quicker delivery of inspection results in latest annual report.